Plain-English translation of NCT07105748 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , rivoceranib, and hepatic arterial infusion chemotherapy (a targeted delivery method that sends medicine directly to the liver) work together to treat advanced mixed hepatocellular-cholangiocarcinoma—a rare cancer that starts in the liver. The study will enroll 45 people and measure how well the medication shrinks tumors and how safe the treatment is.
Advanced mixed hepatocellular-cholangiocarcinoma is a difficult-to-treat cancer, and people with this diagnosis have limited options. Researchers believe combining these three medications may be more effective than existing treatments.
You likely qualify if…
You likely don't qualify if…
You would receive the medication combination over several treatment cycles, with one medication delivered directly into your liver through a special catheter and the others given by infusion or by mouth. You would have regular visits for blood tests, scans to measure your tumor, and check-ins with the research team to monitor how you're responding and manage any side effects. The study continues for as long as the treatment is helping and you can tolerate it.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Fudan University
Enrollment target
~45 participants
Started
August 2025
Primary completion
August 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Peng Wang, MD
Fudan University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.